All In Biotech

Drug Trial Radar · NCT01851707

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone

A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of Duvelisib With Background Methotrexate in Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone

Last checked: Nov 19, 2026Latest source record: Mar 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 322 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

322

Actual

Start

Apr 2013

Primary completion

Dec 2014

Study completion Feb 2015

Sponsor

Lead sponsor
SecuraBioIndustry
Sponsor type
Industry
First posted
May 10, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the safety and efficacy of multiple dose levels of the investigational product (study drug), IPI-145, in combination with methotrexate compared to methotrexate alone in subjects with active moderate-to-severe Rheumatoid Arthritis.

Conditions

  • Rheumatoid Arthritis

Interventions

  • IPI-145Drug

    2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.

  • PlaceboDrug

    2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who achieve a 20% improvement in the American College of Rheumatology Criteria (ACR20) from Baseline to Week 12Time frame: Baseline (Day 1), Weeks 2, 4, 6, 8, 10 and 12

Locations

64 sites in 11 countries. Site status is shown where the registry gives one.

  • Site not named

    Pleven, Bulgaria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Rousse, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Stara Zagora, Bulgaria

  • Site not named

    Targovishte, Bulgaria

  • Site not named

    Varna, Bulgaria

  • Site not named

    Medellín, Antioquia, Colombia

  • Site not named

    Bogota, Cundinamarca, Colombia

  • Site not named

    Bucaramanga, Santander Department, Colombia

  • Site not named

    Frankfurt, Germany

  • Site not named

    Halle, Germany

  • Site not named

    Budapest, Hungary

  • Site not named

    Kecskemét, Hungary

  • Site not named

    Mezőkövesd, Hungary

  • Site not named

    Nyíregyháza, Hungary

  • Site not named

    Veszprém, Hungary

  • Site not named

    Mexico City, Mexico

  • Site not named

    Mexico City, Col Roam Sur, Mexico

  • Site not named

    Mexico City, Del Cuautemoc, Mexico

  • Site not named

    León, Guanajuato, Mexico

  • Site not named

    Guadalajara, Jalisco, Mexico

  • Site not named

    Madero, Mexico DF, Mexico

  • Site not named

    Morelia, Michoacán, Mexico

  • Site not named

    Monterrey, Nuevo León, Mexico

  • Site not named

    San Luis Potosí City, San Luis Potosi, C.P., Mexico

  • Site not named

    Mérida, Yucatán, Mexico

  • Site not named

    Wellington, New Zealand

  • Site not named

    Otahuhu, Auckland, New Zealand

  • Site not named

    Bialystok, Poland

  • Site not named

    Elblag, Poland

  • Site not named

    Krakow, Poland

  • Site not named

    Lublin, Poland

  • Site not named

    Nadarzyn, Poland

  • Site not named

    Poznan, Poland

  • Site not named

    Skierniewice, Poland

  • Site not named

    Sosnowiec, Poland

  • Site not named

    Stalowa Wola, Poland

  • Site not named

    Starachowice, Poland

  • Site not named

    Wroclaw, Poland

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.